{
  "id": "56f780cb09dd18d46b000011",
  "type": "factoid",
  "question": "Which is the target protein of the drug nivolumab?",
  "ideal_answer": "Nivolumab was developed as a monoclonal antibody against programmed death receptor-1, an immune checkpoint inhibitor which negatively regulates T-cell proliferation and activation.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26028407",
    "http://www.ncbi.nlm.nih.gov/pubmed/26448890",
    "http://www.ncbi.nlm.nih.gov/pubmed/26273207",
    "http://www.ncbi.nlm.nih.gov/pubmed/26027431",
    "http://www.ncbi.nlm.nih.gov/pubmed/25897158",
    "http://www.ncbi.nlm.nih.gov/pubmed/26406148"
  ],
  "snippets": [
    {
      "text": "nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26028407",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26027431",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint inhibitor antibody, ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25897158",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " programmed death receptor-1 (PD-1) inhibitors pembrolizumab and nivolumab were approved for the treatment of advanced melanoma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26448890",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nivolumab was developed as a monoclonal antibody against programmed death receptor-1, an immune checkpoint inhibitor which negatively regulates T-cell proliferation and activation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26273207",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26406148",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "programmed death receptor-1"
}